Evidence map›Paper›PMID 38107169›Full record

ArticleRSC medicinal chemistry2023

Development of trisubstituted thiophene-3-arboxamide selenide derivatives as novel EGFR kinase inhibitors with cytotoxic activity.

Priyanka N Makhal, Anika Sood, Arbaz Sujat Shaikh, Lahu N Dayare, Dharmendra Kumar Khatri, Venkata Rao Kaki

Open access · greenAbstract read
In one paragraph

Article in RSC medicinal chemistry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Priyanka N MakhalDepartment of Chemical Sciences, National Institute of Pharmaceutical Education and Research (NIPER) Hyderabad-500037 India kvenkata.rao@niperhyd.ac.in.ORCID https://orcid.org/0000-0003-0833-8738
Anika SoodDepartment of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research (NIPER) Hyderabad-500037 India dkkhatri10@gmail.com.
Arbaz Sujat ShaikhDepartment of Chemical Sciences, National Institute of Pharmaceutical Education and Research (NIPER) Hyderabad-500037 India kvenkata.rao@niperhyd.ac.in.ORCID https://orcid.org/0000-0001-9625-6577
Lahu N DayareDepartment of Chemical Sciences, National Institute of Pharmaceutical Education and Research (NIPER) Hyderabad-500037 India kvenkata.rao@niperhyd.ac.in.
Dharmendra Kumar KhatriDepartment of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research (NIPER) Hyderabad-500037 India dkkhatri10@gmail.com.ORCID https://orcid.org/0000-0001-7066-7706
Venkata Rao KakiDepartment of Chemical Sciences, National Institute of Pharmaceutical Education and Research (NIPER) Hyderabad-500037 India kvenkata.rao@niperhyd.ac.in.ORCID https://orcid.org/0000-0002-2840-861X
National Institute of Pharmaceutical Education and Research (NIPER) - Ahmedabad · INNational Institute of Pharmaceutical Education and Research · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Overexpression of EGFR is one of the eminent oncogenic drivers detected in the development of several human cancers. The increasing incidences of mutation-based resistance in the tyrosine kinase domain call upon the need for the development of a newer class of small-molecule TK inhibitors. Accordingly, a new series of symmetrical trisubstituted thiophene-3-carboxamide selenide derivatives was developed

Identifiers

PMID38107169
PMCPMC10718591
OpenAlexW4387425509

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.